Glenzocimab does not impact glycoprotein VI-dependent inflammatory hemostasis
Open Access
- 30 December 2020
- journal article
- letter
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 106 (7), 2000-2003
- https://doi.org/10.3324/haematol.2020.270439
Abstract
No abstract availableThis publication has 20 references indexed in Scilit:
- Functional significance of the platelet immune receptors GPVI and CLEC-2JCI Insight, 2019
- The contribution of platelet glycoprotein receptors to inflammatory bleeding prevention is stimulus and organ dependentHaematologica, 2018
- Higher neutrophil counts before thrombolysis for cerebral ischemia predict worse outcomesNeurology, 2015
- Single platelets seal neutrophil-induced vascular breaches via GPVI during immune-complex–mediated inflammation in miceBlood, 2015
- Blocking neutrophil diapedesis prevents hemorrhage during thrombocytopeniaThe Journal of Experimental Medicine, 2015
- New advances in treating thrombotic diseases: GPVI as a platelet drug targetDrug Discovery Today, 2014
- Targeting Glycoprotein VI and the Immunoreceptor Tyrosine-Based Activation Motif Signaling PathwayArteriosclerosis, Thrombosis, and Vascular Biology, 2014
- Platelet ITAM signaling is critical for vascular integrity in inflammationJCI Insight, 2013
- Platelet GPVI: a target for antithrombotic therapy?!Trends in Pharmacological Sciences, 2012
- A Humanized Glycoprotein VI (GPVI) Mouse Model to Assess the Antithrombotic Efficacies of Anti-GPVI AgentsThe Journal of pharmacology and experimental therapeutics, 2012